Get the Stockscreener App
40.51
3.54%
-1.485
After Hours:
40.38
-0.13
-0.32%
Moderna Inc stock is traded at $40.51, with a volume of 14.87M.
It is down -3.54% in the last 24 hours and up +18.10% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$41.99
Open:
$37.605
24h Volume:
14.87M
Relative Volume:
1.29
Market Cap:
$15.83B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.6403
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-5.28%
1M Performance:
+18.10%
6M Performance:
+59.05%
1Y Performance:
+30.97%
1-Day Range:
$36.66
$40.80
1-Week Range:
$36.66
$45.50
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
40.51 | 16.41B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
FDA refuses Moderna’s mRNA flu vaccine application - The Hill
Leave it to CBER: Prasad squad socks Moderna with flu RTF - BioWorld MedTech
Moderna Stock Sinks. The Puzzling Reason Its Flu Vaccine Was Rejected. - Barron's
Moderna's FDA clash over flu shot deepens vaccine investment jitters - Axios
FDA refuses to review Moderna’s flu vaccine in latest move against mRNA - Medical Marketing and Media
Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves - Insider Monkey
FDA blindsides Moderna with refusal to review flu vaccine application: ‘We’re pretty confused’ - New York Post
Local health experts question FDA's refusal to review Moderna's application for a new mRNA flu vaccine - GBH
Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance - MedCity News
Moderna shares pare losses; last down down 3.8% - marketscreener.com
Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case (NASDAQ:MRNA) - Seeking Alpha
Moderna (NASDAQ:MRNA) Shares Gap DownWhat's Next? - MarketBeat
Moderna's investigational flu vaccine denied FDA review, shares drop - Proactive financial news
Mexico enlists Moderna to boost mRNA supply for respiratory diseases - Pharmaceutical Technology
U.S. FDA refusing to review mRNA-based flu shot, says Moderna - Toronto Sun
Market Voices: U.S.-Mexico-Canada trade deal, Kraft Heinz, Moderna - Seeking Alpha
Why Moderna Stock Is Sinking Today - GuruFocus
FDA Rejects Moderna's (MRNA) Flu Vaccine Application, Shares Plummet - GuruFocus
MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA - Finviz
FDA Decision Impacts Moderna (MRNA) Shares Amid Vaccine Application Rejection - GuruFocus
FDA declines to review Moderna’s seasonal flu mRNA vaccine - Yahoo Finance
All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us - BioSpace
AI for investors - MLQ.ai
FDA refuses to review Moderna’s mRNA flu vaccine application - AOL.com
FDA’s vaccines chief reportedly overrules staffers to reject Moderna’s flu shot application - Seeking Alpha
FDA refuses to review Moderna flu shot in surprise setback - The Detroit News
Moderna Stock Alert:Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna InvestorsMRNA - marketscreener.com
Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says - MarketWatch
Fda's Vinay Prasad overruled staff to reject Moderna's flu vaccine applicationStat News - marketscreener.com
FDA Refused Moderna's Application For New mRNA Flu Vaccine - News Radio 570 WWNC
Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate - marketscreener.com
Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale - vocal.media
FDA Refuses to Review Moderna’s mRNA Flu Vaccine Application, Sparking Industry Uproar - vocal.media
Moderna stock price target lowered to $24 by BofA on flu vaccine setback - Investing.com India
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology - FinancialContent
Moderna shares fall as FDA declines to review new flu vaccine - BNN Bloomberg
These Stocks Are Today's Movers: Shopify, Moderna, Robinhood, Kraft Heinz, Vertiv, Unity, Cloudflare, Kraft Heinz, Lyft, Mattel, and More -- Barrons.com - 富途牛牛
FDA refuses to review Moderna’s mRNA flu vaccine - BioPharma Dive
The FDA declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten federal vaccine approvals. https://wapo.st/4aa88Iz - facebook.com
Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application - Blockonomi
Moderna (MRNA) Faces Setback with FDA Refusal-to-File Letter for Influenza Vaccine - GuruFocus
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback - GuruFocus
These Stocks Are Today's Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More -- Barrons.com - 富途牛牛
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies - BioSpace
US regulator refuses to review Moderna flu vaccine filing - The Pharma Letter
FDA declines to review Moderna vaccine application: "It should not be controversial" - medwatch.com
Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine. - Barron's
First mRNA vaccine to be produced in UK approved by regulators - AOL.com
FDA rejects Moderna’s application for mRNA flu shot review - Semafor
Moderna Faces FDA Setback on mRNA Flu Vaccine - TipRanks
The vaccine maker Moderna said that the FDA notified the company that the agency would not review its mRNA flu vaccine, the latest sign of federal health policy that has become hostile to vaccine development. - facebook.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
2.09%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):